For example, urolithin A, an ellagitannin metabolite, dose-dependently inhibited (10-50 μM) proliferation and activation of CD4+, by calcium influx impairment through the STIM1/STIM2–Orai1–SOCE pathway [120], but its effect on dermatitis is still unknown. This evidence concerns the gene CD4 and skin disorder.